BackInhibikase Therapeutics Overview

Inhibikase Therapeutics Other Liabilities

Inhibikase Therapeutics's other liabilities is $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Inhibikase Therapeutics Other Liabilities History

Loading

Inhibikase Therapeutics vs. peers: Other Liabilities Comparison

Loading

Inhibikase Therapeutics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Inhibikase Therapeutics (IKT) FAQ

The latest other liabilities for IKT is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Inhibikase Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, IKT's other liabilities moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Inhibikase Therapeutics's operating scale or balance-sheet position.

A other liabilities figure of $0 for IKT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IKT's other liabilities ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Inhibikase Therapeutics's other liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.